| [1] | Gu R, Yang X, Wei H. Molecular landscape and targeted therapy of acute myeloid leukemia. Biomark Res, 2018, 6(1): 32. doi: 10.1186/s40364-018-0146-7 |
| [2] | Dicker F, Haferlach C, Sundermann J, et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia, 2010, 24(8): 1528-1532. doi: 10.1038/leu.2010.124 |
| [3] | Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 2001, 98(6): 1752-1759. doi: 10.1182/blood.V98.6.1752 |
| [4] | Lee LY, Hernandez D, Rajkhowa T, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood, 2017, 129(2): 257-260. doi: 10.1182/blood-2016-10-745133 |
| [5] | Mori M, Kaneko N, Ueno Y, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs, 2017, 35(5): 556-565. doi: 10.1007/s10637-017-0470-z |
| [6] | Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med, 2019, 381(18): 1728-1740. doi: 10.1056/NEJMoa1902688 |
| [7] | Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol, 2017, 18(8): 1061-1075. doi: 10.1016/S1470-2045(17)30416-3 |
| [8] | Li J, Chen Y, Zhu Y, et al. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget, 2015, 6(8): 6448-6458. doi: 10.18632/oncotarget.3361 |
| [9] | DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med, 2020, 383(7): 617-629. doi: 10.1056/NEJMoa2012971 |
| [10] | DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood, 2019, 133(1): 7-17. doi: 10.1182/blood-2018-08-868752 |
| [11] | Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 1996, 10(12): 1911-1918. |
| [12] | Pratz KW, Sato T, Murphy KM, et al. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood, 2010, 115(7): 1425-1432. doi: 10.1182/blood-2009-09-242859 |
| [13] | Grafone T, Palmisano M, Nicci C, et al. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev, 2012, 6(1): e8. doi: 10.4081/oncol.2012.e8 |
| [14] | Kottaridis PD, Gale RE, Linch DC. Flt3 mutations and leukaemia. Br J Haematol, 2003, 122(4): 523-538. doi: 10.1046/j.1365-2141.2003.04500.x |
| [15] | Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 2005, 106(12): 3740-3746. doi: 10.1182/blood-2005-05-2164 |
| [16] | Linch DC, Hills RK, Burnett AK, et al. Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood, 2014, 124(2): 273-276. doi: 10.1182/blood-2014-02-554667 |
| [17] | Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood, 2014, 124(23): 3441-3449. doi: 10.1182/blood-2014-05-578070 |
| [18] | Mesa RA, Jamieson C, Bhatia R, et al. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Netw, 2017, 15(10): 1193-1207. doi: 10.6004/jnccn.2017.0157 |
| [19] | Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129(4): 424-447. doi: 10.1182/blood-2016-08-733196 |
| [20] | Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia, 2000, 14(3): 476-479. doi: 10.1038/sj.leu.2401568 |
| [21] | Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol, 2014, 32(18): 1919-1926. doi: 10.1200/JCO.2013.52.8562 |
| [22] | Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol, 2015, 16(9): 1025-1036. doi: 10.1016/S1470-2045(15)00201-6 |
| [23] | Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol, 2014, 5(3): 65-77. doi: 10.1177/2040620714532123 |
| [24] | Daver N, Cortes J, Ravandi F, et al. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood, 2015, 125(21): 3236-3245. doi: 10.1182/blood-2014-10-605808 |
| [25] | Levis M. Midostaurin approved for FLT3-mutated AML. Blood, 2017, 129(26): 3403-3406. doi: 10.1182/blood-2017-05-782292 |
| [26] | Lever JR, Fergason-Cantrell EA. Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax). Pharmacol Res, 2019, 142: 87-100. doi: 10.1016/j.phrs.2019.01.040 |
| [27] | Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med, 2015, 21(2): 178-184. doi: 10.1038/nm.3788 |
| [28] | DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol, 2018, 93(3): 401-407. doi: 10.1002/ajh.25000 |
| [29] | DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood, 2020, 135(11): 791-803. doi: 10.1182/blood.2019003988 |
| [30] | McMahon CM, Ferng T, Canaani J, et al. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov, 2019, 9(8): 1050-1063. doi: 10.1158/2159-8290.CD-18-1453 |
